Clinical trials: Pandemic Influenza Prevention
Influenza, Virus Diseases
Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults
Over the past decade, avian influenza (AI) has become a major health concern. The development of safe and effective vaccines against avian strains that infect people is important.
- Trial name
- NCT00853255
- Testing
- Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Virus Diseases
Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
Avian influenza (AI), or bird flu, has recently become a major health concern in Asia and other parts of the world. The need for a vaccine to prevent the spread of AI among livestock and to humans is sorely needed.
- Trial name
- NCT00347672
- Testing
- H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pandemic Influenza Vaccine, Prevention
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1) vaccine (whole-virion, aluminium-adjuvanted).
- Conditions
- Pandemic Influenza Vaccine, Prevention, Pandemic Influenza
- Trial name
- NCT00660257
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza A, Pandemic Influenza
H7HLAII DNA Influenza Vaccine
The purpose of this study is to assess safety and immunogenicity of H7HLAII, a DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class…
- Trial name
- H7N9vax-1 (NCT06046092)
- Testing
- H7HLAII
- Where
- Norway
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Influenza
Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine
To determine the tolerability and immunogenicity of FLUVAL P monovalent influenza vaccine in adults and elderly people, with the objective to verify efficacy and tolerability of the study drug.
- Trial name
- NCT01010893
- Testing
- Vaccination with Fluval P and Fluval AB influenza vaccines, Vaccination with Fluval P monovalent influenza vaccine
- Where
- 2 sites in Hungary
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza A Virus, H7N9 Subtype
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
H7N9 avian influenza (AI) viruses have caused a recent outbreak of severe respiratory disease in humans in China. The purpose of this study is to evaluate the safety and immunogenicity of a live attenuated H7N9 A/Anhui/13 ca…
- Trial name
- NCT01995695
- Testing
- Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 influenza vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study of a Pandemic Influenza Vaccine in Elderly Participants
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00376402
- Testing
- H5N1 Pandemic Influenza Vaccine
- Where
- 2 sites in Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Influenza Vaccines
Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity.
- Trial name
- NCT00306995
- Testing
- SB218352_15, SB218352_8, SB218352_4
- Where
- 10 sites in Germany
- Volunteers
- 385 people
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above
Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)
- Trial name
- NCT00620815
- Testing
- Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine, Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- Where
- 2 sites in Germany
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Virus Diseases
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
In the 20th century, influenza pandemics occurred in 1918, 1957, and 1968, and were associated with significant morbidity and mortality.
- Trial name
- NCT00722774
- Testing
- H2N2 1960 AA ca recombinant vaccine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A Virus, H7N9 Subtype
Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old
H7N9 viruses have caused an outbreak of severe respiratory disease in 2013-2014 in China that affected many older adults. This study will evaluate the safety of and immune response to a live attenuated H7N9 vaccine in adults 50…
- Trial name
- NCT02274545
- Testing
- H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Virus Diseases
Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
Over the past decade, avian influenza (AI) has become a major health concern. The development of a safe and effective vaccine against H5N1 infection is important.
- Trial name
- NCT00488046
- Testing
- H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Prevention, Pandemic Influenza Prevention
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu.
- Trial name
- NCT07111078
- Testing
- VRC-FLUMOS0122-00-VP, ALFQ
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309634
- Testing
- 4 adjuvanted pandemic influenza candidate vaccines, 4 non-adjuvanted pandemic influenza candidate vaccines
- Where
- Belgium
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline